526 related articles for article (PubMed ID: 18498129)
1. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
2. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
3. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
4. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
5. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
6. Two ⁹⁰Y-labeled multimeric RGD peptides RGD4 and 3PRGD2 for integrin targeted radionuclide therapy.
Liu Z; Shi J; Jia B; Yu Z; Liu Y; Zhao H; Li F; Tian J; Chen X; Liu S; Wang F
Mol Pharm; 2011 Apr; 8(2):591-9. PubMed ID: 21247151
[TBL] [Abstract][Full Text] [Related]
7. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation.
Janssen M; Frielink C; Dijkgraaf I; Oyen W; Edwards DS; Liu S; Rajopadhye M; Massuger L; Corstens F; Boerman O
Cancer Biother Radiopharm; 2004 Aug; 19(4):399-404. PubMed ID: 15453954
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
9. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.
Dijkgraaf I; Kruijtzer JA; Liu S; Soede AC; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):267-73. PubMed ID: 16909226
[TBL] [Abstract][Full Text] [Related]
10. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
Chakraborty S; Shi J; Kim YS; Zhou Y; Jia B; Wang F; Liu S
Bioconjug Chem; 2010 May; 21(5):969-78. PubMed ID: 20387808
[TBL] [Abstract][Full Text] [Related]
14. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides.
Dijkgraaf I; Yim CB; Franssen GM; Schuit RC; Luurtsema G; Liu S; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):128-37. PubMed ID: 20857099
[TBL] [Abstract][Full Text] [Related]
16. MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides.
Jacobson O; Zhu L; Niu G; Weiss ID; Szajek LP; Ma Y; Sun X; Yan Y; Kiesewetter DO; Liu S; Chen X
Mol Imaging Biol; 2011 Dec; 13(6):1224-33. PubMed ID: 21161690
[TBL] [Abstract][Full Text] [Related]
17. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.
Ahmadi M; Sancey L; Briat A; Riou L; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
Cancer Biother Radiopharm; 2008 Dec; 23(6):691-700. PubMed ID: 19111043
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
Hernandez R; Czerwinski A; Chakravarty R; Graves SA; Yang Y; England CG; Nickles RJ; Valenzuela F; Cai W
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
[TBL] [Abstract][Full Text] [Related]
19. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
20. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
